Concord Biotech Ltd share price logo

Concord Biotech Ltd (CONCORDBIO)


Get free price alerts. Set up your Free investment account to get Live Prices.
Q3 '23 Results
News and Events

Insights on Concord Biotech Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.


    MF Holding Up


    Mutual Funds have increased holdings from 5.58% to 5.65% in Dec 2023 quarter


    Price Rise


    In the last 7 days, CONCORDBIO stock has moved up by 2.5%


    Retail Holding Up


    Retail Investor have increased holdings from 40.44% to 40.46% in Dec 2023 quarter

  • imgNO EFFECT

    Promoter Holding Unchanged


    Promoters holdings remained unchanged at 44.08% of holdings in Dec 2023 quarter


    Profit Down


    Netprofit is down for the last 2 quarters, 81.02 Cr → 77.57 Cr (in ₹), with an average decrease of 4.3% per quarter


    Revenue Fall


    Revenue is down for the last 2 quarters, 270.47 Cr → 252.0 Cr (in ₹), with an average decrease of 6.8% per quarter


    FII Holding Down


    Foreign Institutions have decreased holdings from 7.30% to 7.00% in Dec 2023 quarter


  • Day's Low

    Day's High

  • 52 Week's Low

    52 Week's High

1 Month Return+ 8.56 %
3 Month Return+ 8.21 %
1 Year Return+ 67.15 %
Previous Close₹1,575.90
Upper Circuit-
Lower Circuit-
Market Cap₹16,486.47Cr

Analyst Rating

based on 4 analysts


Based on 4 analysts offering long term price targets for Concord Biotech Ltd. An average target of ₹1592

Source: S&P Global Market Intelligence

Company Information

Concord Biotech Ltd was originally incorporated as Servomed Pharmaceuticals Private Limited at Ahmedabad Gujarat as a Private Limited Company dated November 23 1984 issued by the Registrar of Companies. Thereafter name of the Company was changed to Concord Biotech Limited dated February 16 2001 which became a Public Company and a fresh Certificate of Incorporation dated November 7 2001 was issued by the RoC.The Company is an Indiabased biopharma and one of the leading global developers and manufacturers of select fermentationbased APIs across immunosuppressants and oncology in terms of market share based on volume in supplying to over 70 countries including regulated markets such as the United States Europe and Japan and India. Presently it is engaged in research and development manufacturing marketing and selling of pharmaceutical products. Its API manufacturing facilities are located at Dholka and Limbasi and formulations facility at Valthera in Gujarat.In 2000 the Company was acquired by the Promoter Mr. Sudhir Vaid. In 2016 the Company launched formulation business in India as well as emerging markets including Nepal Mexico Indonesia Thailand Ecuador Kenya Singapore and Paraguay and have further expanded to the United States. It established a facility at Valthera Gujarat.It set up a joint venture in Japan to grow business in 2018.In 2019 the Company received two ANDA approvals. It expanded their business into critical care segment in India. It commenced marketing of Mycophenolate Mofetil Capsules USP 250 mg. In 2020 Mycophenolate Sodium Tablets got launched in the US market.A second API manufacturing facility at Limbasi was launched which commenced operations in July 2021. As of March 31 2022 the Company had 6 fermentationbased immunosuppressant APIs including tacrolimus mycophenolate mofetil mycophenolate sodium cyclosporine sirolimus and pimecrolimus. It had 3 manufacturing facilities in the state of Gujarat India comprising API manufacturing facilities in Dholka and Limbasi and a formulation manufacturing facility in Valthera which were commercialized in 2000 2021 and 2016 respectively. Their total annual installed fermentation capacity for APIs was 1250 m3 as of March 31 2022. It had a total of 41 manufacturing blocks and 387 reactors in the Dholka and Limbasi facilities. As of March 31 2022 the annual installed production capacity of formulation facility in Valthera amounted to 522.64 million units with an average dosage capability of 0.17 million tablets 0.36 million capsules and 646.46 bottles of dry syrup per shift which is defined as eight hours of production. The Company is planning to raise capital from Public by issuing o 20925652 Equity Shares through Offer for Sale..

Share Price: ₹1571.80 per share as on 20 Jun, 2024 04:01 PM
Market Capitalisation: ₹16,486.47Cr as of today
Revenue: ₹318.97Cr as on March 2024 (Q1 24)
Net Profit: ₹95.02Cr as on March 2024 (Q1 24)
Listing date: 18 Aug, 2023
Chairperson Name: SUDHIR JAIRAM VAID
OrganisationConcord Biotech Ltd
E-voting on sharesClick here to vote

Key events for Concord Biotech Ltd

  • Insider Selling at Concord Biotech Ltd Raises Concerns - 17 Jun, 2024

    Over the past year, many insiders at Concord Biotech Limited have sold shares worth ₹159m. In the last three months, insider Kanishka Kapoor sold ₹144m worth of shares, indicating that some insiders may not consider the shares to be cheap. However, insiders own 50% of the company's shares, which could suggest that it is run in the interest of all shareholders.

  • Concord Biotech Receives GMP Certificate for Gujarat Facility - 06 Jun, 2024

    Ireland's health products regulatory authority has issued an EU GMP certificate to Concord Biotech for Unit II of its Valthera facility in Gujarat, India.

  • Concord Biotech Shares Surge After Stake Sale And Upgrades - 29 May, 2024

    Pharmaceutical company Concord Biotech's shares surged after Ontario Inc offloaded a stake worth Rs 519 crore and Kotak Institutional Equities upgraded the stock to add. Jefferies has a hold call on the stock with a target of Rs 1,410 per share.

  • Block Deal Sends Concord Biotech Shares Lower - 28 May, 2024

    Ontario Inc planned to sell 3.4% stake in Concord Biotech via a block deal valued at Rs 468.4 crore. The transaction was completed with Citigroup as the sole book runner for the sale. Following the trade, the stock fell 2.4%. However, trading volumes surged over 66 times the two-week average daily volume.

  • Ontario Inc. Plans to Sell Stake in Concord Biotech - 27 May, 2024

    Concord Biotech is set to see a block trade of 3.4% equity as shareholder Ontario Inc. plans to sell shares worth Rs 468.40 crore at a floor price of Rs 1,320 per share.

  • Concord Biotech Q4FY24 Profit Increases by 3.9% - 24 May, 2024

    Concord Biotech Ltd reported a 3.9% increase in profit to Rs 95 crore and a 17% surge in revenue to Rs 319 crore for Q4FY24 compared to the same period last year.

Concord Biotech Ltd Valuation

Concord Biotech Ltd in the last 5 years

  • Overview

  • Trends

Lowest (36.27x)

October 4, 2023

Today (53.53x)

June 19, 2024

Industry (65.08x)

June 19, 2024

Highest (56.63x)

April 30, 2024


Mutual Fund Holdings

Funds Holdings
HSBC Small Cap Fund Fund Direct GrowthHSBC Small Cap Fund Fund Direct Growth0.85%
DSP Healthcare Fund Direct GrowthDSP Healthcare Fund Direct Growth3.87%
Invesco India Multicap Fund Direct Plan Growth OptionInvesco India Multicap Fund Direct Plan Growth Option1.45%
UTI Small Cap Fund Direct GrowthUTI Small Cap Fund Direct Growth1.11%
Edelweiss Small Cap Fund Direct GrowthEdelweiss Small Cap Fund Direct Growth1.13%

Shareholding Pattern

InvestorsHoldings %Prev. 1 periods3M change
Promoter Holdings
Foreign Institutions
Mutual Funds
Retail Investors

Frequently Asked Questions

  • Get a PAN card.
  • Open a Demat account.
  • Open a Trading account.
  • Link your Demat account to your Trading account.
  • Fund your Trading account.
  • Place an order to buy Concord Biotech Ltd shares.

Concord Biotech Ltd (CONCORDBIO) share price today is ₹1571.8

Concord Biotech Ltd is listed on NSE

Concord Biotech Ltd is listed on BSE

  • Today’s highest price of Concord Biotech Ltd is ₹1583.2.
  • Today’s lowest price of Concord Biotech Ltd is ₹1557.55.

PE Ratio of Concord Biotech Ltd is 53.53

PE ratio = Concord Biotech Ltd Market price per share / Concord Biotech Ltd Earnings per share

Today’s traded volume of Concord Biotech Ltd(CONCORDBIO) is 54.01K.

Today’s market capitalisation of Concord Biotech Ltd(CONCORDBIO) is ₹16486.47Cr.

Concord Biotech Ltd(CONCORDBIOPrice
52 Week High
52 Week Low

Concord Biotech Ltd(CONCORDBIO) share price is ₹1571.8. It is down -8.88% from its 52 Week High price of ₹1725

Concord Biotech Ltd(CONCORDBIO) share price is ₹1571.8. It is up 74.63% from its 52 Week Low price of ₹900.05

Concord Biotech Ltd(CONCORDBIOReturns
1 Day Returns
1 Month Returns
3 Month Returns
1 Year Returns